Developer docs
API playgroundTry for free, no card

Search company profiles

Swiss

Full company profile

uuid000981f

Namestring
Swiss
Legal namestring
Swiss Parenterals Limited
Websiteurl
swiss.in
Company typeenum
Private
Founded yearint
1986
Descriptiontext

Swiss Parenterals Limited is an Ahmedabad-based pharmaceutical contract development and manufacturing organization (CDMO) founded in 1986, specializing in generic and specialty sterile injectables alongside a broader portfolio spanning inhaled anesthetics, orals, ophthalmic/nasal, semi-solids, nutritional OTC, ayurvedic/cosmetics, and veterinary products. The company operates three cGMP-compliant manufacturing units in Ahmedabad equipped with dedicated HVAC/BMS/EMS systems, automated sterile and oral dosage lines, lyophilization, pre-filled syringe filling, and cephalosporin/betalactam/carbapenem dry powder injectable capabilities, supported by GLP-certified QC laboratories and ERP-driven batch release and ICH stability testing. Its product portfolio exceeds 250 SKUs across approximately 190 unique molecules with over 1,000 approved dossiers, and the company holds EU-GMP, PIC/s, ANVISA, TGA, and Cofepris certifications enabling exports to 80+ countries under both its own brand and partner labels.

Swiss generates revenue through three primary streams: (1) international distribution partnerships, supplying both own-brand and partner-labeled generic/specialty injectables to B2B distributors in 80+ countries with regulatory dossier support; (2) contract manufacturing services for medicinal products (Rx, OTC, and dietary supplements) under cGMP-compliant production with full analytical support; and (3) technology transfer and licensing services including analytical method transfer, AMV per ICH guidelines, and dossier creation/submission support. Pricing is not publicly disclosed; quotes are negotiated based on volume and specification. As of November 2025, Swiss became a wholly-owned subsidiary of Eris Lifesciences via a share-swap acquisition of the remaining 30% stake, with Naishadh Shah appointed Managing Director and FY27 identified as a significant year for the company's international expansion under Eris' strategic umbrella.

Short descriptiontext

Swiss Parenterals is an Ahmedabad-based CDMO manufacturing generic and specialty sterile injectables, inhaled anesthetics, orals, ophthalmic, and nutritional products across three cGMP-certified units, exporting to 80+ countries for international distribution partners and as a wholly-owned Eris Lifesciences subsidiary since November 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersAhmedabad, India
HQ citystring
Ahmedabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectables manufacturing, contract pharmaceutical manufacturing, generic pharmaceuticals export, inhaled anesthesia products, lyophilized injection production
Industry5 codes
1Generic Finished Dosage Form (FDF) Manufacturing
CodeHLAIABAHPrimaryYes
2Generic Hospital & Institutional Products
CodeHLAIABALPrimaryNo
3Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
CodeHLAIAJAFPrimaryNo
4Medical Supplies & Consumables Wholesale (Non-Device)
CodeCRAOAHAEPrimaryNo
5Pharmaceutical & Life Sciences Warehousing (GDP-Compliant)
CodeTLAIACADPrimaryNo
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Drugs and Druggists' Sundries Merchant Wholesalers4242
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Exports
TypeOne Time License
Description

Swiss exports pharmaceutical products under its own brand name to over 80 countries globally, as well as products labeled in distribution partners' brands. Revenue is generated through direct B2B sales to international distribution partners with regulatory support provided across all activities.

swiss.in
2Contract Manufacturing Services
TypeProfessional Services
Description

The company offers customized contract manufacturing services with micro-control and monitoring and full analytical support at cGMP-compliant production plants. Services include manufacturing of medicinal products (Rx and OTC) and dietary supplements for third-party clients.

swiss.in
3Technology Transfer and Licensing
TypeLicensing Royalties
Description

Provides technology transfer services to distribution partners, including analytical method transfer, AMV in accordance with ICH guidelines, and comprehensive dossier creation and submission support.

swiss.in
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Swiss Parenterals is a contract development and pharmaceutical manufacturing company that produces sterile injectable dosage forms (lyophilized injections, pre-filled syringes, dry powder vials, liquid ampoules), inhaled anesthetics, oral solid dosages, ophthalmic and nasal products, semi-solids, and nutritional supplements. The company exports to 80+ countries under its own brand and partner brands, and provides contract manufacturing, technology transfer, analytical method transfer, dossier creation, and regulatory support to distribution partners and third-party clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Products exported to 80+ countries globally
+1 more record
Product overview1 text field

Swiss Parenterals is a third-generation family-owned Indian pharmaceutical company leveraging over 25 years of expertise in generic and specialty pharmaceuticals. The company operates as a manufacturer and exporter of sterile injectable products, offering a comprehensive portfolio across seven core product categories: Parenterals (injectable formulations including lyophilized injections, anaesthetics, and antibiotics), Inhaled Anesthesia (surgical anesthesia products), Ophthalmic and Nasal (eye drops, ear drops, and nasal sprays), Orals (tablets, capsules, and oral suspensions), Semi-Solids (topical creams, ointments, and gels), Nutritional/OTC (supplements and wellness products), and Ayurvedic/Cosmetics (traditional medicine and personal care). With over 1,000 approved dossiers and more than 190 unique molecules, Swiss exports to 80+ countries under its own brand name and partner brands. The company operates three manufacturing units in Ahmedabad, Gujarat, equipped with cGMP-compliant production facilities and serves international markets through regulatory approvals including EU-GMP, ANVISA, TGA, PIC/s, and Cofepris.

Product and service1 record
1Parenterals
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large Indian generic pharmaceutical company with a dedicated sterile injectables franchise and global commercial footprint; competes with Swiss in international tender and distribution channels but at significantly greater scale and brand recognition.

TypeDirect peer
Description

Indian-headquartered sterile injectable manufacturer with global regulatory approvals and a B2B contract development and manufacturing model nearly identical to Swiss Parenterals, including lyophilized injectables, pre-filled syringes, and complex dosage forms sold through international distribution partners.

TypeBroad incumbent
Description

India's largest pharmaceutical company with a broad sterile injectables and specialty portfolio (including inhalation anesthesia via Taro and other units), serving as a broader incumbent competitor across Swiss's product categories.

TypeBroad incumbent
Description

Global contract development and manufacturing organization with a strong sterile injectable and inhalation anesthesia franchise, competing with Swiss for partner-led contract manufacturing and technology transfer opportunities.

TypeEmerging player
Description

Indian generic pharmaceutical company with regulated market focus and a portfolio of sterile injectables, oral solids, and soft gels, often partnering with international distributors in similar channels to Swiss.

TypeDirect peer
Description

Indian CDMO and specialty injectable producer with capabilities in lyophilized injectables, pre-filled syringes, and transdermal systems, targeting similarly regulated international markets through dossier and partner-led distribution.

TypeBroad incumbent
Description

Indian pharmaceutical major with global sterile injectable manufacturing operations and an established international distribution presence that overlaps with Swiss's dossier-driven export business.

TypeDirect peer
Description

Major Indian generic pharmaceutical manufacturer with a sizable sterile injectables franchise and a global export footprint spanning 150+ countries, overlapping directly with Swiss on lyophilized and liquid injectable generics.

TypeEmerging player
Description

Indian generic manufacturer with growing injectable and international business, including US filings and sterile injectable capacity, comparable in scale and mid-tier positioning to Swiss.

TypeDirect peer
Description

India-based specialty sterile injectable and biological products company focused on complex dosage forms (lyophilized, pre-filled syringes) for hospital and institutional channels — closely comparable to Swiss's higher-value injectable portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Swiss

Pharmaceutical Manufacturingswiss.in

Swiss Parenterals is an Ahmedabad-based CDMO manufacturing generic and specialty sterile injectables, inhaled anesthetics, orals, ophthalmic, and nutritional products across three cGMP-certified units, exporting to 80+ countries for international distribution partners and as a wholly-owned Eris Lifesciences subsidiary since November 2025.

What Swiss does

Swiss Parenterals Limited is an Ahmedabad-based pharmaceutical contract development and manufacturing organization (CDMO) founded in 1986, specializing in generic and specialty sterile injectables alongside a broader portfolio spanning inhaled anesthetics, orals, ophthalmic/nasal, semi-solids, nutritional OTC, ayurvedic/cosmetics, and veterinary products. The company operates three cGMP-compliant manufacturing units in Ahmedabad equipped with dedicated HVAC/BMS/EMS systems, automated sterile and oral dosage lines, lyophilization, pre-filled syringe filling, and cephalosporin/betalactam/carbapenem dry powder injectable capabilities, supported by GLP-certified QC laboratories and ERP-driven batch release and ICH stability testing. Its product portfolio exceeds 250 SKUs across approximately 190 unique molecules with over 1,000 approved dossiers, and the company holds EU-GMP, PIC/s, ANVISA, TGA, and Cofepris certifications enabling exports to 80+ countries under both its own brand and partner labels.

Swiss generates revenue through three primary streams: (1) international distribution partnerships, supplying both own-brand and partner-labeled generic/specialty injectables to B2B distributors in 80+ countries with regulatory dossier support; (2) contract manufacturing services for medicinal products (Rx, OTC, and dietary supplements) under cGMP-compliant production with full analytical support; and (3) technology transfer and licensing services including analytical method transfer, AMV per ICH guidelines, and dossier creation/submission support. Pricing is not publicly disclosed; quotes are negotiated based on volume and specification. As of November 2025, Swiss became a wholly-owned subsidiary of Eris Lifesciences via a share-swap acquisition of the remaining 30% stake, with Naishadh Shah appointed Managing Director and FY27 identified as a significant year for the company's international expansion under Eris' strategic umbrella.

Swiss firmographics

Firmographics
Name
Swiss
Legal name
Swiss Parenterals Limited
Website
https://swiss.in
Company type
Private
Founded year
1986
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Swiss Parenterals is an Ahmedabad-based CDMO manufacturing generic and specialty sterile injectables, inhaled anesthetics, orals, ophthalmic, and nutritional products across three cGMP-certified units, exporting to 80+ countries for international distribution partners and as a wholly-owned Eris Lifesciences subsidiary since November 2025.
Ownership category
akta.pro rank

Swiss industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (4242)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
akta.pro secondary industries
Generic Hospital & Institutional Products (HLAIABAL), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF), Medical Supplies & Consumables Wholesale (Non-Device) (CRAOAHAE), Pharmaceutical & Life Sciences Warehousing (GDP-Compliant) (TLAIACAD)

Keywords

  • Sterile injectables manufacturing
  • Contract pharmaceutical manufacturing
  • Generic pharmaceuticals export
  • Inhaled anesthesia products
  • Lyophilized injection production

Where Swiss is headquartered

Location

Headquarters

HQ city
Ahmedabad
HQ country
India
HQ region
Asia

Offices3 records

Markets served

Swiss business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Exports: Swiss exports pharmaceutical products under its own brand name to over 80 countries globally, as well as products labeled in distribution partners' brands. Revenue is generated through direct B2B sales to international distribution partners with regulatory support provided across all activities.
  2. Contract Manufacturing Services: The company offers customized contract manufacturing services with micro-control and monitoring and full analytical support at cGMP-compliant production plants. Services include manufacturing of medicinal products (Rx and OTC) and dietary supplements for third-party clients.
  3. Technology Transfer and Licensing: Provides technology transfer services to distribution partners, including analytical method transfer, AMV in accordance with ICH guidelines, and comprehensive dossier creation and submission support.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Swiss product offering

Product offering

Core offering

Swiss Parenterals is a contract development and pharmaceutical manufacturing company that produces sterile injectable dosage forms (lyophilized injections, pre-filled syringes, dry powder vials, liquid ampoules), inhaled anesthetics, oral solid dosages, ophthalmic and nasal products, semi-solids, and nutritional supplements. The company exports to 80+ countries under its own brand and partner brands, and provides contract manufacturing, technology transfer, analytical method transfer, dossier creation, and regulatory support to distribution partners and third-party clients.

Product overview

Swiss Parenterals is a third-generation family-owned Indian pharmaceutical company leveraging over 25 years of expertise in generic and specialty pharmaceuticals. The company operates as a manufacturer and exporter of sterile injectable products, offering a comprehensive portfolio across seven core product categories: Parenterals (injectable formulations including lyophilized injections, anaesthetics, and antibiotics), Inhaled Anesthesia (surgical anesthesia products), Ophthalmic and Nasal (eye drops, ear drops, and nasal sprays), Orals (tablets, capsules, and oral suspensions), Semi-Solids (topical creams, ointments, and gels), Nutritional/OTC (supplements and wellness products), and Ayurvedic/Cosmetics (traditional medicine and personal care). With over 1,000 approved dossiers and more than 190 unique molecules, Swiss exports to 80+ countries under its own brand name and partner brands. The company operates three manufacturing units in Ahmedabad, Gujarat, equipped with cGMP-compliant production facilities and serves international markets through regulatory approvals including EU-GMP, ANVISA, TGA, PIC/s, and Cofepris.

Differentiator

Problem solved

Functional benefit

Products and services

  • Parenterals

Quantifiable outcome

  • Products exported to 80+ countries globally
  • +1 more outcomes

Companies that use Swiss

Customer profile

Segments3 records

Ideal customer profiles3 records

Swiss technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Swiss partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Swiss competitors and assessment

Company assessment

Broad incumbents

  • Dr. Reddy's Laboratories: Large Indian generic pharmaceutical company with a dedicated sterile injectables franchise and global commercial footprint; competes with Swiss in international tender and distribution channels but at significantly greater scale and brand recognition.
  • Sun Pharmaceutical Industries: India's largest pharmaceutical company with a broad sterile injectables and specialty portfolio (including inhalation anesthesia via Taro and other units), serving as a broader incumbent competitor across Swiss's product categories.
  • Piramal Pharma Solutions: Global contract development and manufacturing organization with a strong sterile injectable and inhalation anesthesia franchise, competing with Swiss for partner-led contract manufacturing and technology transfer opportunities.
  • Cadila Healthcare (Zydus): Indian pharmaceutical major with global sterile injectable manufacturing operations and an established international distribution presence that overlaps with Swiss's dossier-driven export business.

Direct peers

  • Gland Pharma: Indian-headquartered sterile injectable manufacturer with global regulatory approvals and a B2B contract development and manufacturing model nearly identical to Swiss Parenterals, including lyophilized injectables, pre-filled syringes, and complex dosage forms sold through international distribution partners.
  • Shilpa Medicare: Indian CDMO and specialty injectable producer with capabilities in lyophilized injectables, pre-filled syringes, and transdermal systems, targeting similarly regulated international markets through dossier and partner-led distribution.
  • Aurobindo Pharma: Major Indian generic pharmaceutical manufacturer with a sizable sterile injectables franchise and a global export footprint spanning 150+ countries, overlapping directly with Swiss on lyophilized and liquid injectable generics.
  • Bharat Serums and Vaccines: India-based specialty sterile injectable and biological products company focused on complex dosage forms (lyophilized, pre-filled syringes) for hospital and institutional channels — closely comparable to Swiss's higher-value injectable portfolio.

Emerging players

  • Strides Pharma Science: Indian generic pharmaceutical company with regulated market focus and a portfolio of sterile injectables, oral solids, and soft gels, often partnering with international distributors in similar channels to Swiss.
  • Alembic Pharmaceuticals: Indian generic manufacturer with growing injectable and international business, including US filings and sterile injectable capacity, comparable in scale and mid-tier positioning to Swiss.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Swiss compliance and trust

Trust signal

Compliance5 records

Swiss financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Swiss leadership team

Management profile

Number of profiles

Profiles1 record

Swiss funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Swiss M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swiss

What does Swiss do?

Swiss Parenterals is a contract development and pharmaceutical manufacturing company that produces sterile injectable dosage forms (lyophilized injections, pre-filled syringes, dry powder vials, liquid ampoules), inhaled anesthetics, oral solid dosages, ophthalmic and nasal products, semi-solids, and nutritional supplements. The company exports to 80+ countries under its own brand and partner brands, and provides contract manufacturing, technology transfer, analytical method transfer, dossier creation, and regulatory support to distribution partners and third-party clients.

Is Swiss a public or private company?

Swiss is a private company. It is classified as corporate owned and is currently operating.

When was Swiss founded?

Swiss was founded in 1986. It employs 501 to 1,000 people.

Where is Swiss based?

Swiss is headquartered in Ahmedabad, India, in the Asia region.

How does Swiss make money?

Three revenue lines are on record. Pharmaceutical Product Exports are the primary driver. The others are contract Manufacturing Services and technology Transfer and Licensing.

Who are Swiss's main competitors?

Broad incumbents on record are Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Piramal Pharma Solutions and Cadila Healthcare (Zydus). Direct peers are Gland Pharma, Shilpa Medicare, Aurobindo Pharma and Bharat Serums and Vaccines. Emerging players are Strides Pharma Science and Alembic Pharmaceuticals.

Does Swiss have an API?

No public API is recorded for Swiss.

What industry is Swiss in?

Swiss's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 42421 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CNBCTV18Eris Lifesciences' Q1 profit jumps 21%, but margins come under pressureGujarat-headquartered Eris Lifesciences reported a 20.7% year-on-year increase in consolidated profit after tax to ₹142.39 crore for Q1 FY2026, with revenue from operations rising 13% to ₹873.25 crore. However, the company's EBITDA margin contracted to 34% from 36% in the year-ago period as total expenses grew 13% to ₹695.75 crore. The company has been actively expanding through acquisitions including buying the remaining 30% stake in Swiss Parenterals for ₹423.3 crore, partnering with Natco Pharma to commercialize Semaglutide in India, and acquiring Velbiom Probiotics' branded probiotics business for ₹50 crore.NDTV ProfitFlights To UAE, Kuwait Affected, Bahrain Closes Airspace After Iran Launches AttackIran launched missile attacks targeting Kuwait and Bahrain on Wednesday, prompting the US military to confirm Iranian missiles were fired but failed or were shot down, after which the US responded with strikes on an Iranian military ground control station on Qeshm Island near the Strait of Hormuz. Multiple Middle Eastern countries, including Bahrain which closed its airspace, along with UAE and Kuwait, experienced significant flight disruptions as airlines cancelled routes to the region amid escalating tensions. Several major airlines including Aegean, Air Baltic, Air Canada, Air France KLM, IAG, Lufthansa, SWISS, and ITA Airways suspended flights to destinations like Dubai, Tel Aviv, Beirut, Riyadh, and Baghdad as a precautionary measure.The Times of IndiaWest Asia war: Indian carriers see dip in international carriage while foreign carriers climb in Jan-March quarter - The Times of IndiaThe DGCA released data showing international flyers to and from India fell 1.2% to 1.91 crore in Jan-March 2026, with Indian carriers carrying 80.9 lakh passengers — a nearly 10% decline — while foreign airlines carried 1.1 crore, up 6% from the same period last year. Foreign non-Gulf carriers like Lufthansa, British Airways, and SWISS capitalised on Gulf carriers' disrupted operations by adding flights to India, whereas Indian carriers — constrained by Pakistan airspace closure, soaring fuel costs, and Air India's flight cuts — could not fill that gap. IndiGo overtook the Air India Group as the largest carrier in this period, carrying 38.2 lakh versus the combined Air India Group's 37.7 lakh passengers.EsgnewsSWISS Partners With Metafuels To Secure Future Synthetic SAF SupplySWISS and Lufthansa Group have partnered with Swiss SAF technology company Metafuels to support synthetic sustainable aviation fuel development and secure future procurement access ahead of expected regulatory quotas in Switzerland and the EU from 2030. Metafuels' aerobrew process converts sustainable methanol into aviation fuel designed for use in existing aircraft and infrastructure, with a demonstration plant being established in Switzerland and a commercial plant under development in Rotterdam. The partnership is structured as a strategic move by airlines to lock in long-term access to synthetic fuels and manage exposure to tightening regulation, rising demand, and supply scarcity in the decarbonizing aviation sector.RenewablesnowSWISS, Metafuels tie up to scale SAF commercialisationMetafuels has signed a supply partnership with SWISS and Lufthansa Group, marking the company's first aviation-sector partner to scale sustainable aviation fuel (SAF) commercialization. The partnership aligns with upcoming synthetic fuel additive quotas set to be adopted in Switzerland and the EU from 2030 onward. Metafuels uses its proprietary "aerobrew" process to convert renewable methanol into jet fuel, claiming up to 90% lower lifecycle emissions than fossil kerosene, and is currently building a demonstration plant in Villigen, Switzerland and a first commercial facility in Rotterdam.Travel And Tour WorldSWISS Joins Forces with Metafuels to Accelerate the Development of Sustainable Aviation Fuel, Paving the Way for Significant Emission Reductions and a Greener Aviation IndustrySWISS has entered into a strategic collaboration with Swiss sustainable aviation fuel technology company Metafuels to develop and scale SAF solutions for aviation, ensuring the airline has long-term access to synthetic fuels. Metafuels has pioneered an "aerobrew" process that converts green methanol into aviation-grade fuel and is establishing a demonstration production facility in Villigen, Switzerland, along with a first commercial plant in Rotterdam. SWISS and its parent company Lufthansa Group are also exploring long-term procurement contracts for SAF ahead of new synthetic fuel quotas set to be introduced in Switzerland and the EU by 2030.GreenAir NewsSWISS signs with methanol-to-SAF developer Metafuels in drive to access synthetic aviation fuelsSwiss International Air Lines (SWISS) has partnered with Zurich-based Metafuels to develop and access synthetic aviation fuels, with plans to establish production facilities in Switzerland and Rotterdam. The collaboration aims to secure early access to sustainable aviation fuels (SAF), supporting Switzerland's goal of becoming a hub for SAF research and innovation.Aviation Week NetworkSwiss Forms SAF Partnership With MetafuelsThe article reports a partnership between Swiss and Metafuels related to SAF (Sustainable Aviation Fuel). It is published as part of Aviation Daily's market briefing.Investing.comAnalysis-As Iran war jolts Air India, Lufthansa and Cathay pounce on fast-growing market By ReutersAir India cut thousands of flights due to the Iran war and Pakistan's airspace ban, prompting Lufthansa and Cathay Pacific to add services to India. Foreign airlines' share of India-origin international scheduled flights rose to 58.4% in March-May, up from 51.2% a year earlier. Air India's U.S. routes fell 77.4% year-on-year, and it suspended Delhi-Chicago flights.The Times of IndiaSWISS reviews evacuation messaging after passengers carry bags on slides | Delhi News - The Times of IndiaSWISS has begun reviewing its communication on evacuation procedures after passengers on a Zurich-bound Airbus A330 at Delhi airport carried cabin bags onto emergency slides during an emergency evacuation on Sunday morning. The aircraft aborted takeoff after engine failure and suspected engine fire, and while 245 people were evacuated, four passengers were hospitalized with injuries. The airline is awaiting clearance from Indian authorities to inspect the engine, while India's Aircraft Accident Investigation Bureau is investigating the incident.